Multiomics and Multidimensional Testing for Efficacy Monitoring of Patients with Lymphoma.
10.19746/j.cnki.issn.1009-2137.2023.03.019
- Author:
Xin-Hua WANG
1
;
Yan-Xin YANG
1
;
Ying-Jun WANG
1
;
Bao-Hong YUE
2
;
Ming-Zhi ZHANG
3
Author Information
1. Department of Oncology, The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052, Henan Province, China,Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou 450052, Henan Province, China.
2. Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
3. Department of Oncology, The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052, Henan Province, China,Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou 450052, Henan Province, China,E-mail: mingzhi_zhang1@163.com.
- Publication Type:Journal Article
- Keywords:
cfDNA;
efficacy evaluation;
lymphoma;
peripheral blood;
whole genome sequencing
- MeSH:
Humans;
Multiomics;
Lymphoma/genetics*;
Cell-Free Nucleic Acids;
Genomics/methods*;
DNA Copy Number Variations;
Ubiquitin-Protein Ligases
- From:
Journal of Experimental Hematology
2023;31(3):746-752
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the role of a new blood-based, multiomics and multidimensional method for evaluating the efficacy of patients with lymphoma.
METHODS:10 ml peripheral blood was extracted from each patient, and the genomic copy number aberrations (CNA) and fragment size (FS) were evaluated by low-depth whole genome sequencing of cfDNA, and the level of a group of plasma tumor marker (PTM) were detected at the same time. The cancer efficacy score (CES) was obtained by standardized transformation of the value of above three numerical indexes, and the changes of CES before and after treatment were compared to evaluate the patient's response to the treatment regimen.
RESULTS:A total of 35 patients' baseline data were collected, of which 23 cases (65.7%) had elevated CES values. 18 patients underwent the first time test. The results showed that the CES value of 9 patients with positive baseline CES decreased significantly at the first test, and the efficacy evaluation was PR, which was highly consistent with the imaging evaluation results of the same period. At the same time, the CNA variation spectrum of all patients were evaluated and it was found that 23 patients had partial amplification or deletion of chromosome fragments. The most common amplification site was 8q24.21, which contains important oncogenes such as MYC. The most common deletion sites were 1p36.32, 4q21.23, 6q21, 6q27, 14q32.33, and tumor suppressor-related genes such as PRDM1, ATG5, AIM1, FOXO3 and HACE1 were expressed in the above regions, so these deletions may be related to the occurrence and development of lymphoma.
CONCLUSION:With the advantages of more convenience, sensitivity and non-invasive, this multiomics and multidimensional efficacy detection method can evaluate the tumor load of patients with lymphoma at the molecular level, and make more accurate efficacy evaluation, which is expected to serve the clinic better.
